Hair Loss Informations: Hair loss treatments and Hair transplant 

Forum Haarausfall
(+/- to specify search)

Menu
Home
Hair and growth of hair
Types of hair loss
Your life with hair loss
Treatment
Treatment Alopecia Areata
Hair transplantation
Non-surgical hair replacement
Future treatments
Message Board

Log In
Username

Password

Remember Me



Search Articles



AddThis Social Bookmark Button


NEOSH101 - new clinical Phase 2 data
NEOSIL ANNOUNCES POSITIVE PHASE 2 DATA FOR NEOSH101, AN INVESTIGATIONAL TREATMENT FOR ANDROGENETIC ALOPECIA

Emeryville, CA – January 4, 2007 – Neosil, Inc., a privately held dermatology-focused pharmaceutical company, today announced positive Phase 2a clinical data demonstrating that its lead product, NEOSH101, increased hair growth significantly in men diagnosed with androgenetic alopecia, also known as pattern hair loss (PHL). Androgenetic alopecia or PHL, caused by a combination of genetic and hormonal factors, is noticeable in about 20 percent of the population by age 20 and increases steadily with age. By age 50 approximately half of the U.S. population will have some degree of PHL. “

Based on the results of this study, we are quite encouraged by the increase in hair growth observed after such a short once-daily treatment regimen with NEOSH101,” said Vera H. Price, MD, FRCP(C), Professor of Clinical Dermatology, Department of Dermatology, University of California, San Francisco.

In a randomized, double-blind Phase 2a clinical study, conducted in Germany, 50 men with androgenetic alopecia (Norwood/Hamilton grades III-IV) received once-daily topical treatments of NEOSH101 or placebo over two 14-day treatment periods, which were separated by a one-month drug-free interval. Hair growth was measured using an objective photographic, computer-based analysis for up to 24 weeks after initiation of therapy. Results show that NEOSH101 was safe and well tolerated. A statistically significant increase in total hair count (4.8%, p=0.04), and cumulative hair thickness (3.7%, p=0.02) were observed, with peak effects occurring eight weeks following the second treatment cycle.

“The results of this study are encouraging, particularly the finding of increased numbers of terminal hairs, those hairs that are thicker than 40 microns and desirable for scalp coverage,” said Andria Langenberg, M.D., Vice President of Clinical Development at Neosil. “We plan to initiate a Phase 2b study to evaluate daily treatment with NEOSH101 for a longer treatment period in men with PHL.”

About Neosil

Neosil, Inc. is a privately held dermatology-focused pharmaceutical company that was funded in November 2004 with a $32 million investment by MPM Capital and Burrill & Company, following initial incubation funding by Shalon Ventures, LP. In addition to its topical hair growth product, NEOSH101, Neosil is developing a broad-spectrum topical anti-microbial agent for acne and anti-infective use. Article Manager module by by George! Software.




What's Related
These might interest you as well
Article Manager

Impressum


Copyright © Appalachian State University 2002 - 2003
This Site is powered by phpWebSite © The Web Technology Group, Appalachian State University
phpWebSite is licensed under the GNU LGPL
Forum Haarausfall allgemein Forum Haarausfall Frauen Forum Alopecia Areata (kreisrunder Haarausfall)
Forum Haartransplantation Haartransplantation- Infos